clinical trial · NCT07414836
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines·phase1·not yet recruiting·n = 84
Advanced Solid TumorBG-C0979Tislelizumab
brief summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BG-C0979 monotherapy or in combination with tislelizumab in participants with selected advanced solid tumors. The study will consist of Phase 1a (Dose Escalation and Safety Expansion) and Phase 1b (Dose Expansion).
started
Apr 30, 2026
primary completion
Apr 30, 2029
completion
Apr 30, 2029
last updated
Feb 17, 2026
official title
A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-C0979 in Patients With Selected Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol